Elsevier

Neurobiology of Disease

Volume 8, Issue 6, December 2001, Pages 982-992
Neurobiology of Disease

Regular Article
Neuropathological Characterization of Mutant Amyloid Precursor Protein Yeast Artificial Chromosome Transgenic Mice

https://doi.org/10.1006/nbdi.2001.0446Get rights and content

Abstract

Mutations in the amyloid precursor protein (APP) gene result in elevated production and deposition of the 42 amino acid β-amyloid (Aβ1–42) peptide and early-onset Alzheimer's disease (AD). To accurately examine the effect of the APP FAD mutations in vivo, we introduced yeast artificial chromosomes (YACs) containing the entire genomic copy of human APP harboring FAD mutations into transgenic mice. Our current results demonstrate that mutant APP YAC transgenic mice exhibit many features characteristic of human AD, including regional deposition of Aβ with preferential deposition of Aβ1–42, extensive neuritic abnormalities as evidenced by staining with APP, ubiquitin, neurofilament, and hyperphosphorylated tau antibodies, increased markers of inflammation, and the overlapping deposition of Aβ with apolipoproteins E and J. Our results also suggest that APP YAC transgenic mice possess unique pathological attributes when compared to other transgenic mouse models of AD that may reflect the experimental design of each model.

References (66)

  • I. Kovacs et al.

    Cholinergic structures and neuropathologic alterations in the olfactory bulb of Alzheimer's disease brain samples

    Brain Res.

    (1998)
  • A. Kulkarni-Narla et al.

    Manganese and copper-zinc superoxide dismutases in the human olfactory mucosa: Increased immunoreactivity in Alzheimer's disease

    Exp. Neurol.

    (1996)
  • B.T. Lamb et al.

    YAC transgenics and the study of genetics and human disease

    Curr. Opin. Genet. Dev.

    (1995)
  • C.A. Lemere et al.

    Sequence of deposition of heterogeneous amyloid β-peptides and APOE in Down syndrome: Implication for initial events in amyloid plaque formation

    Neurobiol. Dis.

    (1996)
  • E. McGowan et al.

    Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes

    Neurobiol. Dis.

    (1999)
  • C. Murphy et al.

    Olfactory dysfunction in Down's Syndrome

    Neurobiol. Aging

    (1996)
  • Y. Namba et al.

    Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease

    Brain Res.

    (1991)
  • E.M. Rockenstein et al.

    Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease

    J. Biol. Chem.

    (1995)
  • G. Thinakaran et al.

    Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo

    Neuron

    (1996)
  • L.L. Weber et al.

    Presenilin-1 immunoreactivity is localized intracellularly in Alzheimer's disease brain, but not detected in amyloid plaques

    Exp. Neurol.

    (1997)
  • S.E. Arnold et al.

    Cellular and molecular neuropathology of the olfactory epithelium and central olfactory pathways in Alzheimer's disease and schizophrenia

    Ann. N.Y. Acad. Sci.

    (1998)
  • A.W. Bacon et al.

    Very early changes in olfactory functioning due to Alzheimer's disease and the role of apolipoprotein E in olfaction

    Ann. N.Y. Acad. Sci.

    (1998)
  • K.S. Chen et al.

    Neurodegenerative Alzheimer-like pathology in PDAPP 717V → F transgenic mice

    Prog. Brain Res.

    (1998)
  • J.F. Couse et al.

    Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta

    Science

    (1999)
  • R.B. DeMattos et al.

    Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

    Proc. Natl. Acad. Sci. USA

    (2001)
  • D.P. Devanand et al.

    Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up

    Am. J. Psychiatry

    (2000)
  • S.A. Frautschy et al.

    Microglial response to amyloid plaques in APPsw transgenic mice

    Am. J. Pathol.

    (1998)
  • D. Games et al.

    Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

    Nature

    (1995)
  • M. Goedert et al.

    Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205

    Neurosci. Lett.

    (1995)
  • M. Hattori et al.

    A novel method for making nested deletions and its application for sequencing of a 300 kb region of the human APP locus

    Nucleic Acids Res.

    (1997)
  • M. Hattori et al.

    The DNA sequence of human chromosome 21. The chromosome 21 mapping and sequencing consortium

    Nature

    (2000)
  • K. Hsiao et al.

    Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice

    Science

    (1996)
  • Cited by (62)

    • The role of neuropathological markers in the interpretation of neuropsychiatric disorders: Focus on fetal and perinatal programming

      2018, Neuroscience Letters
      Citation Excerpt :

      High levels of oxidative damage in AD patients have been confirmed [91]. The following neuropathological sequence of events in AD has been hypothesized: regional deposition of beta amyloid, extensive neuritic abnormalities, hyper-phosphorylated tau protein, increased inflammation and deposition of beta amyloid with apolipoprotein E and J [51]. Neuropathological markers similar to those found in AD have been reported in chromosome 3 dementias, familial British dementia and familial Danish dementia, [86].

    • Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease

      2016, Neurobiology of Disease
      Citation Excerpt :

      A number of transgenic mouse models have been created that overexpress amyloid precursor protein (APP) and successfully reproduce Aβ deposition and age-associated cognitive deficits (Ashe and Zahs, 2010; Eriksen and Janus, 2007; Savonenko and Borchelt, 2008; Webster et al., 2014). Interestingly, in APP transgenic mice with different strain backgrounds, promoters, and AD-linked mutations, female mice tend to show more severe plaque pathology than males (Callahan et al., 2001; Hirata-Fukae et al., 2008; Hutter-Paier et al., 2004; Kulnane and Lamb, 2001; LaClair et al., 2013; Lee et al., 2002; Perez et al., 2011; Wang et al., 2003). There have been relatively few studies addressing sex differences in cognitive deficits; these have pointed to the development of more severe or earlier declines in female APP transgenic mice than in males (Berger-Sweeney et al., 1995; Clinton et al., 2007; King and Arendash, 2002; King et al., 1999; Pistell et al., 2008).

    • Short-term treatment with tolfenamic acid improves cognitive functions in alzheimer's disease mice

      2013, Neurobiology of Aging
      Citation Excerpt :

      Therefore, after the characterization of learning and memory impairment in female hemizygous R1.40 transgenic mice, 5 and 50 mg/kg/d tolfenamic acid was administered to female R1.40 mice aging between 14 and 21 months via oral gavage for 34 days and learning and memory functions were assessed in the Morris water maze (MWM) and the Y-maze. On day 35, mice were euthanized and AD-associated proteins including SP1, APP, and soluble and insoluble Aβ1–40 and Aβ1–42 were assessed in the frontal cortex, which displays extensive AD pathology in this animal model (Kulnane and Lamb, 2001; Lehman et al., 2003). The transgenic mouse model R1.40 was used for this study.

    • Genetic mouse models of neurodegenerative diseases

      2011, Progress in Molecular Biology and Translational Science
    • CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models

      2010, American Journal of Pathology
      Citation Excerpt :

      Thus, the apparent discrepancy in the results of the two studies may be reflective of the cellular location of the Aβ aggregates and is supported by our findings that the steady-state levels of Aβ in predepositing CX3CR1-deficient APPPS1 and R1.40 animals remained unchanged (data not shown). Furthermore, we did not observe any obvious alterations in neurodegeneration in the APPPS1;Cx3cr1−/− and R1.40;Cx3cr1−/− animals, consistent with previous studies demonstrating no overt neurodegeneration in either the APPPS1 or R1.40 animals.21,36 Notably, similar types of studies also did not detect robust neuronal loss in aged 3xTg animals,62 and it remains to be determined how the neuronal loss observed by Fuhrmann et al via two photon microscopy relates to the amyloid toxicity observed in the 3xTg, APPPS1 and R1.40 mouse models.

    View all citing articles on Scopus
    View full text